Compare FRD & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FRD | AGEN |
|---|---|---|
| Founded | 1965 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 134.3M | 124.4M |
| IPO Year | 1995 | 1999 |
| Metric | FRD | AGEN |
|---|---|---|
| Price | $19.13 | $4.63 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $14.50 |
| AVG Volume (30 Days) | 25.7K | ★ 909.4K |
| Earning Date | 02-09-2026 | 05-11-2026 |
| Dividend Yield | ★ 0.84% | N/A |
| EPS Growth | N/A | ★ 100.00 |
| EPS | ★ 1.46 | N/A |
| Revenue | ★ $121,157,278.00 | $42,877,086.00 |
| Revenue This Year | N/A | $107.63 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $13.09 | ★ $8.89 |
| Revenue Growth | 55.82 | ★ 89.95 |
| 52 Week Low | $14.01 | $1.96 |
| 52 Week High | $24.37 | $7.34 |
| Indicator | FRD | AGEN |
|---|---|---|
| Relative Strength Index (RSI) | 60.34 | 64.33 |
| Support Level | $18.15 | $3.92 |
| Resistance Level | $19.52 | $5.20 |
| Average True Range (ATR) | 0.69 | 0.37 |
| MACD | 0.21 | 0.11 |
| Stochastic Oscillator | 86.51 | 75.74 |
Friedman Industries Inc is engaged in the manufacturing and processing of steel products. The company's operating segments include flat-roll products and Tubular Products. It generates maximum revenue from the flat-roll products segment. The company's products and services include Temper Pass, Cut-To-Length, Whole Coils, Toll Processing, Electric Resistance Welded Pipe (ERW), New Mill Secondary, and Pipe Finishing Services.
Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.